WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced that its MEDRAD ® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the ...

WHIPPANY, N.J., March 04, 2026--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD ® MRXperion ...

Bayer Healthcare’s Medrad unit bought a Washington State-based vascular disease device maker, Pathway Medical Technologies. The company’s Jetstream franchise of devices promise a minimally invasive ...

The US Food and Drug Administration (FDA) has granted expanded clearance to Bayer’s Medrad MRXperion, broadening the magnetic resonance (MR) injection system’s application across a wider range of MRI ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global contrast injectors market since 2015 and the market is poised to grow by USD 613.47 million during 2020-2024, progressing at a CAGR of ...

Medrad, a subsidiary of Bayer HealthCare, has signed an agreement to acquire Possis Medical for about $361 million. With 2006 sales of $478 million, Medrad is a leading provider of contrast injection ...

Bayer AG (OTCMKTS:BAYRY) is among the best German stocks to buy according to analysts. On March 5, Bayer AG (OTCMKTS:BAYRY) announced that the FDA has cleared its MEDRAD MRXperion MR injector system ...

Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...

Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions Expanded Tesla compatibility captures low- to high-end field magnetic resonance (MR) systems, now ...